We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Randox Quality Control Launches Acusera Anti-Müllerian Hormone (AMH) Control

By LabMedica International staff writers
Posted on 08 Jun 2022

Randox (Crumlin, UK) has launched a new Acusera Control for the accurate and reliable testing of Anti-Müllerian Hormone (AMH). More...

An AMH test is often used to check a woman’s ability to produce eggs that can be fertilized for pregnancy, thus helping women to make informed decisions about their health. The new Randox Acusera AMH control is designed for use as a third-party control for the quantitative determination of AMH. Available in a liquid frozen format for convenience and reduced handling errors, the control should be treated in the same manner as a patient sample.

The Acusera AMH is a true third-party control providing an unbiased assessment of performance and is manufactured using human serum, ensuring commutable sample matrix. It provides assayed target values, thus eliminating the need to assign values in-house. The control is available at recommended cut-off values for AMH and has 30-day stability when stored at +2°C to +8°C.

Related Links:
Randox


New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.